Business Context and Reporting Period
The supplied filing is Brooks Automation, Inc.’s Form 10-K for the fiscal year ended September 30, 2012; it does not identify Azenta, Inc. as the registrant. Brooks provided automation, vacuum and instrumentation solutions for semiconductor, industrial technology and life-science markets. Its reported segments were Brooks Product Solutions, Brooks Global Services, Brooks Life Science Systems and Contract Manufacturing, the last of which was sold in June 2011.
Fiscal 2012 reflected a strategic shift toward life sciences and other non-semiconductor markets, while semiconductor capital-equipment demand weakened. Semiconductor capital equipment represented 54% of revenue, versus 65% in fiscal 2011 and 71% in fiscal 2010.
Financial Performance and Liquidity
| Metric | FY2012 | FY2011 | Change |
|---|---|---|---|
| Revenue | $519.5 million | $688.1 million | Down 25% |
| Gross profit | $173.5 million | $223.0 million | Down 22% |
| Gross margin | 33.4% | 32.4% | Up 1.0 percentage point |
| Operating income | $9.6 million | $79.6 million | Down 88% |
| Net income attributable to Brooks | $136.8 million | $130.4 million | Up 5% |
| Diluted EPS | $2.08 | $2.01 | Up 3% |
| Operating cash flow | $36.0 million | $87.7 million | Down 59% |
| Adjusted EBITDA | $58.9 million | $113.2 million | Down 48% |
Reported net income was substantially affected by a $121.8 million deferred tax benefit from reducing the valuation allowance against deferred tax assets. Excluding this non-cash tax benefit, the filing indicates materially weaker underlying profitability. FY2012 also included an $8.9 million pension-settlement charge, $3.3 million of restructuring charges and a $3.0 million in-process research and development expense.
At September 30, 2012, cash, cash equivalents and marketable securities totaled $200.2 million, including $54.6 million of cash and cash equivalents. Working capital was $266.3 million and total assets were $742.0 million. The balance sheet showed total liabilities of $92.7 million and stockholders’ equity of $648.7 million. The filing does not show material outstanding borrowings; interest expense was only $14,000 for the year.
Cash used in investing activities was $21.0 million, including $9.2 million for the Celigo acquisition, $8.7 million of capital expenditures and a $3.0 million strategic investment. Cash used in financing activities was $19.2 million, primarily reflecting $21.0 million of dividends. The company paid quarterly dividends of $0.08 per share and declared another $0.08 dividend payable in December 2012.
Material Changes Versus the Prior Comparable Period
- Revenue declined by $168.6 million, reflecting the divestiture of Contract Manufacturing, a $70.4 million decline in Brooks Product Solutions revenue and a $2.9 million decline in Global Services revenue. These decreases were partly offset by $42.0 million of higher Life Science Systems revenue.
- Brooks Product Solutions revenue fell 16% to $380.9 million, while Global Services revenue fell 3% to $86.0 million.
- Life Science Systems revenue increased 396% to $52.6 million, primarily from the RTS, Nexus and Celigo acquisitions. Segment operating loss improved from $4.7 million to $3.1 million.
- Consolidated gross margin improved despite lower revenue because of a more favorable mix, including higher-margin life-science revenue and the removal of lower-margin Contract Manufacturing revenue. Product Solutions gross margin declined to 33.5% from 38.1%, and Global Services gross margin declined to 29.8% from 35.7%.
- R&D expense increased to $47.5 million from $39.8 million, while SG&A declined slightly to $101.2 million from $102.5 million.
- The company reduced its workforce by 118 employees and expects approximately $10 million of annualized savings from fiscal 2012 workforce reductions.
- Cash flow from operations fell to $36.0 million from $87.7 million, substantially due to lower operating performance and the non-cash deferred-tax benefit included in net income.
- Prior-period financial information was revised for errors in accounting for the ULVAC Cryogenics equity-method investment. Management concluded the errors were not individually or collectively material to prior filings, and the revision had no net effect on prior-period cash flows.
Guidance, Outlook, Risks and Unusual Items
Management stated that weakness in semiconductor capital-equipment demand was expected to continue into the early part of fiscal 2013 and that fourth-quarter fiscal 2012 revenue provided a lower near-term comparison point for Brooks Product Solutions. The company expected semiconductor equipment to remain a key market while pursuing growth through life sciences and adjacent technologies.
On October 29, 2012, after the reporting date, Brooks acquired Crossing Automation for approximately $63.1 million in cash, subject to a working-capital adjustment. Crossing reportedly had approximately $51 million of trailing twelve-month revenue, $3 million of operating profit and approximately 41% gross margins.
- The semiconductor capital-equipment industry is cyclical, creating substantial volatility in revenue, margins, inventory and cash flow.
- Customer concentration remained significant: the top ten customers represented approximately 43% of fiscal 2012 revenue, and one customer represented 13%.
- Backlog declined to $81.1 million from $99.7 million, and orders may be canceled or rescheduled without significant penalty.
- International sales represented approximately 56% of fiscal 2012 revenue, exposing the company to foreign-exchange, geopolitical, regulatory and collection risks.
- Goodwill totaled $88.4 million and passed the annual impairment test, but the Life Science Systems reporting unit exceeded carrying value by only 5%; weaker projections could produce a future impairment.
- Total contractual obligations were $86.2 million, including $65.3 million of purchase commitments and other obligations. Unrecognized tax benefits and related interest totaled $7.6 million.
- The company maintained $3.3 million of outstanding letters of credit and had approximately $0.9 million of remaining payments under a guaranteed Mexico lease.
- Management stated that ordinary-course legal proceedings were not expected to have a material adverse effect. The filing also disclosed prior litigation-related insurance proceeds of approximately $3.3 million recorded as a reduction of SG&A.
Important Facts for Investors to Verify
- Confirm the registrant identity: the supplied filing is for Brooks Automation, Inc., not Azenta, Inc.
- Separate the $121.8 million non-cash deferred-tax benefit from recurring earnings and assess the company using operating income, operating cash flow and adjusted EBITDA.
- Evaluate the sustainability of the life-science growth strategy, including integration of RTS, Nexus and Celigo and the subsequent Crossing acquisition.
- Monitor semiconductor demand, Product Solutions margins, backlog and inventory reserves, which were $23.2 million at year-end.
- Review customer concentration, particularly the 13% customer and top-ten concentration of approximately 43% of revenue.
- Assess goodwill impairment sensitivity for Life Science Systems, where estimated fair value exceeded carrying value by only 5%.
- Verify post-year-end cash usage and liquidity after the $63.1 million Crossing acquisition, dividends and ongoing purchase commitments.